SCIENCEPLUS INTERNATIONAL CONFERENCE
Taipei, Taiwan 25-12-2021EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) after Non-1st-Line Osimertinib Resistance: A Review of EGFR-Dependent Targets of Treatment Options
WRL Cited • 117